Pathologists currently rely on chemical staining of tissue samples to perform disease diagnosis. However, these techniques are highly prone to variations due to the clinical environment and staining protocol. Midinfrared spectroscopic imaging has the potential to overcome several of these problems by providing quantitative molecular information that can be used for highly specific tissue classification [1] [4] . However, there are bottlenecks that limit clinical applicability of these methods. For example, Fouriertransform infrared (FTIR) spectroscopic images are often time-consuming to acquire at a spectral resolution and SNR level that is viable for reliable classification. In addition, algorithms are computationally intensive and data sets can be terabytes in size. This research focuses on improving the clinical viability of mid-infrared spectroscopy by utilizing a QCL based imaging system, which allows feature selection from hyperspectral images (HSI) using a Genetic Algorithm and Fisher's Discriminant Analysis as a fitness function (GA-FDA) and classification of HSI images using Random Forest classifier with the optimized feature subsets selected by GA-FDA [3] . We demonstrate that GA-FDA is very promising feature selection algorithm with performance superior to unsupervised as well as supervised feature selection algorithms while being compatible with optimized QCL imaging methods.
Hyperspectral images are acquired using both FTIR spectroscopic imaging (Cary 620, Agilent) and a SPERO QCL imaging system (Daylight Solutions). MIR spectroscopy relies on the Beer-Lambert law and the absorbance is given by taking measurments of the light transmitted both with and without the sample present. These images are then pre-processed using baseline correction and normalization to the Amide I spectral band (1650 cm -1 ). Imaging of one Tissue Micro Array (TMA) with an 8 cm -1 spectral resolution, 5.5 m spatial resolution, and 40 co-adds takes 15 hours on the FTIR spectroscope. Reducing the long imaging hours and processing time while achieving clinically usable classification results are main goals of this study.
The proposed GA-FDA algorithm is compared with other dimensionality reduction algorithms including PCA, mRMR, and Bhattacharya Distance (BD). GA evaluates each genome (i.e. feature subspace) from the population with FDA and ranks them according to their fitness scores. Fisher's discriminant analysis seeks to find a linear transformation T � FDA to a new reduced dimension feature subspace that maximizes fisher's ratio:
Here, S b and S w define between-class and within-class scatter. The GA algorithm with FDA as a fitness function will look for features which maximize fisher's ratio (i.e. the fitness score of each gnome) when the T � FDA projection is applied on them.
Optimized features and neighboring baseline points from the feature selection algorithm are used for cell type classification using a Random Forest Classifier. The results are comparable with the use of whole spectra for the classification while significantly increasing computation efficiency. Validation of results is done on completely separate data sets. We found that GA-FDA performs better than PCA, mRMR and BA on complex data (Figure 2 ). The key point of GA is that it selects features subsets, whereas mRMR and BA select individual features. Hence, GA avoids selection of correlated features which is highly probable for algorithms which select features on an individual basis.
Conclusion
Classification based on spectral signature provides high accuracy for cancer-relevant tissue types. Dimension reduction using localized metrics (individual wavelengths) provides the potential for informed imaging using tunable QCLs, dramatically reducing image acquisition time. 
